Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
West Pharmaceutical ServicesWST +0.65%94 Equity-to-Asset is 0.73 as of Jun. 2026, which is 4% above its 10-year median of 0.70. GuruFocus rates WST with a GF Score™ of 94/100 and a GF Value™ of $356.53 (Fairly Valued). The stock has 8 warning signs investors should review. Among 852 Medical Devices & Instruments companies, West Pharmaceutical Services ranks better than 63.73% on this metric.
West Pharmaceutical Services (NYSE:WST) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
West Pharmaceutical Services Equity-to-Asset Related Terms
West Pharmaceutical Services Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
West Pharmaceutical Services Equity-to-Asset Chart
For the Medical Instruments & Supplies subindustry, West Pharmaceutical Services's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
West Pharmaceutical Services Equity-to-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, West Pharmaceutical Services's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where West Pharmaceutical Services's Equity-to-Asset falls into.
West Pharmaceutical Services Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
West Pharmaceutical Services's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
West Pharmaceutical Services (WST) has a Equity-to-Asset of 0.73 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on West Pharmaceutical Services and its competitors. This is near median its historical median of 0.70. Over the past decade, West Pharmaceutical Services' Equity-to-Asset has ranged from 0.65 to 0.76. According to the industry distribution chart, West Pharmaceutical Services ranks #309 out of 852 companies in the Medical Devices & Instruments industry, placing it in the top 36.3%.
Is West Pharmaceutical Services' Equity-to-Asset too high?
West Pharmaceutical Services' current Equity-to-Asset of 0.73 is near median its 10-year median of 0.70. Over the past 10 years, this metric has ranged from a low of 0.65 to a high of 0.76. The Medical Devices & Instruments industry median Equity-to-Asset is 0.64. West Pharmaceutical Services' value of 0.73 is 14.1% above this industry median. Based on the distribution chart, West Pharmaceutical Services ranks #309 out of 852 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, West Pharmaceutical Services has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does West Pharmaceutical Services' Equity-to-Asset compare to RMD and COO?
According to the Medical Devices & Instruments industry distribution chart, West Pharmaceutical Services ranks #309 out of 852 companies for Equity-to-Asset. This puts West Pharmaceutical Services in the upper half of its industry. The industry median Equity-to-Asset is 0.64. West Pharmaceutical Services' value of 0.73 is 14.1% above this benchmark. Historically, West Pharmaceutical Services' own Equity-to-Asset has ranged from 0.65 to 0.76 over the past decade. While the company's 10-year median is 0.70 vs. the industry median of 0.64, West Pharmaceutical Services has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Devices & Instruments company?
The median Equity-to-Asset among Medical Devices & Instruments companies is 0.64, based on 852 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. West Pharmaceutical Services's current Equity-to-Asset of 0.73 is 14.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on West Pharmaceutical Services and its competitors. For the Medical Devices & Instruments industry, the median Equity-to-Asset is 0.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. West Pharmaceutical Services's current Equity-to-Asset is 0.73, which is near median its own 10-year median of 0.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is West Pharmaceutical Services stock overvalued right now?
Based on GuruFocus' analysis, West Pharmaceutical Services (WST) is currently considered Fairly Valued. The stock's GF Value™ is $356.53, compared to a current price of $351.02 — trading 1.5% below its estimated fair value. The current Equity-to-Asset is 0.73, which is near median its 10-year median of 0.70 and 14.1% above the Medical Devices & Instruments industry median of 0.64. West Pharmaceutical Services' overall GF Score™ is 94/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For West Pharmaceutical Services (WST), the current Equity-to-Asset is 0.73 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is West Pharmaceutical Services (WST) Overvalued in 2026?
Based on GuruFocus' analysis, West Pharmaceutical Services stock appears to be undervalued.
The current stock price of $351.02 is trading 1.5% below its estimated GF Value™ of $356.53.
GuruFocus considers West Pharmaceutical Services to be Fairly Valued.
Key valuation signals for WST:
Equity-to-Asset: 0.73 (near median its 10-year median of 0.70)
GF Value™: $356.53 vs. price of $351.02 (1.5% below fair value)
Industry Position: 14.1% above the Medical Devices & Instruments median (#309 of 852)
No single metric tells the full story. See the WST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
94GF Score
Get the complete analysis for WST
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WST has been successfully added to your 
